Pleiotropic effects of growth hormone and insulin-like growth factor (IGF)-1 on biological aging: Inferences from moderate caloric-restricted animals

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 54, Issue 12, 1999, Pages

  Sonntag, William E ^a   Lynch, Colleen D ^a   Cefalu, William T ^a   Ingram, Rhonda L ^a   Bennett, Sean A ^a   Thornton, Phillip L ^a   Khan, Amir S ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; MESSENGER RNA; SOMATOMEDIN C;

ADAPTATION; AGING; ARTICLE; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BREAST CANCER; CALORIC RESTRICTION; CELL DIVISION; GLUCOSE BLOOD LEVEL; GROWTH HORMONE RELEASE; LIFESPAN; LUNG CANCER; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR;

ANIMALIA;

EID: 0033450849     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/54.12.B521     Document Type: Article

References (214)

1. Masoro EJ, ed. Handbook of Physiology, Section 11: Aging. New York: Oxford University Press; 1995.
2. Masoro EJ. Aging: current concepts. In: Masoro EJ, ed. Handbook of Physiology, Section 11: Aging. New York: Oxford University Press; 1995:3-24.
3. Timiras PS. Neuroendocrinology of aging: retrospective, current, and prospective views. In: Meites J, ed. Neuroendocrinology of Aging. New York: Plenum Press; 1983:5-30.
4. Reichlin S. Neuroendocrinology. In: Williams RH, ed. Textbook of Endocrinology. 5th ed. Philadelphia: WB Saunders; 1974;774-831.
5. Weaver DR. The suprachiasmatic nucleus: a 25-year retrospective [Review; 248 refs]. J Biolog Rhythms. 1998;13:100-112.
6. Miller JD, Morin LP, Schwartz WJ, Moore RY. New insights into the mammalian circadian clock [Review; 230 refs]. Sleep. 1996;19:641-667.
7. Meites J. Neuroendocrinology of Aging. New York: Plenum Press; 1983.
8. McCay CM, Sperling G, Barnes LL. Growth, aging, chronic diseases and lifespan in rats. Arch Biochem Biophys. 1943;2:469-479.
9. Yu BP, Masoro EJ, Murata I, Bertrand HA, Lynd FT. Life span study of SPF Fischer 344 male rats fed ad libitum or restricted diets: longevity, growth, lean body mass and disease. J Gerontol. 1982;37:130-141.
10. Weindruch R, Walford RL. The Retardation of Aging and Disease by Dietary Restriction. Springfield, IL: Charles C Thomas; 1988.
11. Weindruch R, Walford RL, Fligiel S, Guthrie D. The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. J Nutr. 1986;116:641-654.
12. Iwasaki K, Gleiser CA, Masoro EJ, McMahan CA, Seo EJ, Yu BP. Influence of the restriction of individual dietary components on longevity and age-related disease of Fischer rats: the fat component and the mineral component. J Gerontol Biol Sci. 1988;43:B13-B21.
13. Weindruch R, Walford RL. Dietary restriction in mice beginning at 1 year of age: effect on life-span and spontaneous cancer incidence. Science. 1982;215:1415-1418.
14. Bronson RT, Lipman RD. Reduction in rate of occurrence of age related lesions in dietary restricted laboratory mice. Growth Dev Aging. 1991;55:169-184.
15. Lipman JM, Turturro A, Hart RW. The influence of dietary restriction on DNA repair in rodents: a preliminary study [Review; 31 refs]. Mech Ageing Dev. 1989;48:135-143.
16. Turturro AT, Hart RW. DNA repair mechanisms in aging. In: Schiapelli D, Migaki G, eds. Comparative Biology of Major Age-Related Diseases. New York: Alan Liss; 1984:351-361.
17. Hart RW, Turturro AT, Pegram RA, Chou MW. Effects of caloric restriction on the maintenance of genetic fidelity. In: Sutherland BM, Woodhead AD, eds. DAN Damage and Repair in Human Tissues. New York: Plenum Press; 1990:351-361.
18. Djuric Z, Lu MH, Lewis SM, et al. Oxidative DNA damage levels in rats fed low-fat, high-fat, or calorie-restricted diets. Toxicol Appl Pharmacol. 1992;115:156-160.
19. Hart RW, Leakey JE, Chou M, Duffy PH, Allaben WT, Feuers RJ. Modulation of chemical toxicity by modification of caloric intake [Review; 36 refs]. Adv Exp Med Biol. 1992;322:73-81.
20. Birchenall-Sparks MC, Roberts MS, Staecker J, Hardwick JP, Richardson A. Effect of dietary restriction on liver protein synthesis in rats. J Nutr. 1985;115:944-950.
21. Ricketts WG, Birchenall-Sparks MC, Hardwick JP, Richardson A. Effect of age and dietary restriction on protein synthesis by isolated kidney cells. J Cell Physiol. 1985;125:492-498.
22. Sonntag WE, Lenham JE, Ingram RL. Effects of aging and dietary restriction on tissue protein synthesis: relationship to plasma insulin-like growth factor-1. J Gerontol Biol Sci. 1992;47:B159-B163.
23. Verdery RB, Ingram DK, Roth GS, Lane MA. Caloric restriction increases HDL2 levels in rhesus monkeys (Macaca mulatta). Am J Physiol. 1997;273:E714-E719.
24. McCarter RJ. Role of caloric restriction in the prolongation of life [Review; 53 refs]. Clin Geriatr Med. 1995;11:553-565.
25. Weindruch R. The retardation of aging by caloric restriction: studies in rodents and primates [Review; 26 refs]. Toxicol Pathol. 1996;24:742-745.
26. Richardson A, Cheung HT. Current concepts: I. The relationship between age-related changes in gene expression, protein turnover, and the responsiveness of an organism to stimuli [Review; 42 refs]. Life Sci. 1982;31: 605-613.
27. Walter CA, Grabowski DT, Street KA, Conrad CC, Richardson A. Analysis and modulation of DNA repair in aging [Review; 84 refs]. Mech Ageing Dev. 1997;98:203-222.
28. Florini JR, Harned JA, Richman RA, Weiss JP. Effect of rat age on serum levels of growth hormone and somatomedins. Mech Ageing Dev. 1981;15:165-176.
29. Sonntag WE, Steger RW, Forman LJ, Meites J. Decreased pulsatile release of growth hormone in old male rats. Endocrinology. 1980;107: 1875-1879.
30. Rudman D, Feller AG, Cohn L, Shetty KR, Rudman IW, Draper MW. Effects of human growth hormone on body composition in elderly men [Review]. Horm Res. 1991;36(Suppl 1):73-81.
31. Sonntag WE, Hylka VW, Meites J. Growth hormone restores protein synthesis in skeletal muscle of old male rats. J Gerontol. 1985;40: 689-694.
32. Haley-Zitlin V, Richardson A. Effect of dietary restriction on DNA repair and DNA damage [Review; 32 refs]. Mutat Res. 1993;295:237-245.
33. Sonntag WE. An overview of the biological actions and neuroendocrine regulation of growth hormone. In: Gass GH, Kaplan HM, eds. Handbook of Endocrinology. 2nd ed. Boca Raton, FL: CRC Press; 1996;171-202.
34. Li CH, Evans HM, Simpson ME. Isolation and properties of the anterior pituitary hypophyseal growth hormone. J Biol Chem. 1945;159:353-356.
35. Finkelstein JW, Roffwarg HP, Boyar RM, Kream J, Hellman L. Age-related change in the twenty-four-hour spontaneous secretion of growth hormone. J Clin Endocrinol Metab. 1972;35:665-670.
36. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging [Review]. Endocr Rev. 1993;14:20-39.
37. Cohick WS, Clemmons DR. The insulin-like growth factors [Review; 137 refs]. Annu Rev Physiol. 1993;55:131-153.
38. Lopez-Femandez J, Sanchez-Franco F, Velasco B, Tolon RM, Pazos F, Cacicedo L. Growth hormone induces somatostatin and insulin-like growth factor I gene expression in the cerebral hemispheres of aging rats. Endocrinology. 1996;137:4384-4391.
39. Murphy LJ, Friesen HG. Differential effects of estrogen and growth hormone on uterine and hepatic insulin-like growth factor I gene expression in the ovariectomized hypophysectomized rat. Endocrinology. 1988; 122:325-332.
40. Yamamoto H, Murphy LJ. Enzymatic conversion of IGF-I to des(1-3)IGF-I in rat serum and tissues: a further potential site of growth hormone regulation of IGF-I action. J Endocrinol. 1995;146:141-148.
41. Daughaday WH. A personal history of the origin of the somatomedin hypothesis and recent challenges to its validity. Perspect Biol Med. 1989;32: 194-211.
42. Isaksson OG, Lindahl A, Nilsson A, Isgaard J. Action of growth hormone: current views [Review; 45 refs]. Acta Paediatr Scand [Suppl]. 1988;343:12-18.
43. Steiger A, Guldner J, Hemmeter U, Rothe B, Wiedemann K, Holsboer F. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology. 1992;56:566-573.
44. Born J, Muth S, Fehm HL. The significance of sleep onset and slow wave sleep for nocturnal release of growth hormone (GH) and cortisol. Psychoneuroendocrinology. 1988;13:233-243.
45. Tannenbaum GS, Martin JB. Evidence for an endogenous ultradian rhythm governing growth hormone secretion in the rat. Endocrinology. 1976;98:562-570.
46. Ling N, Esch F, Bohlen P, Brazeau P, Wehrenberg WB, Guillemin R. Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor. Proc Natl Acad Sci USA. 1984;81:4302-4306.
47. Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300:276-278.
48. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179:77-79.
49. Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 1984;115:1952-1957.
50. Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L, Hintz RL. Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science. 1981;212: 1279-1281.
51. Laron Z, Doron M, Arnikan B. Plasma growth hormone in men and women over 70 years of age. Med Sports Phys Activity Aging. 1970;4: 126-129.
52. Carlson HE, Gillin JC, Gorden P, Snyder F. Absence of sleep-related growth hormone peaks in aged normal subjects and in acromegaly. J Clin Endocrinol Metab. 1972;34:1102-1105.
53. Johanson AJ, Blizzard RM. Low somatomedin-C levels in older men rise in response to growth hormone administration. Johns Hopkins Med J. 1981;149:115-117.
54. Rudman D, Kutner MH, Rogers CM, Lubin MF, Fleming GA, Bain RP. Impaired growth hormone secretion in the adult population: relation to age and adiposity. J Clin Invest. 1981;67:1361-1369.
55. Sonntag WE, Steger RW, Forman LJ, Meites J. Decreased pulsatile release of growth hormone in old male rats. Endocrinology. 1980;107: 1875-1879.
56. Florini JR, Harned JA, Richman RA, Weiss JP. Effect of rat age on serum levels of growth hormone and somatomedins. Mech Ageing Dev. 1981; 15:165-176.
57. Sonntag WE, Hylka VW, Meites J. Growth hormone restores protein synthesis in skeletal muscle of old male rats. J Gerontol. 1985;40:689-694.
58. Shibasaki T, Shizume K, Nakahara M, et al. Age-related changes in plasma growth hormone response to growth hormone-releasing factor in man. J Clin Endocrinol Metab. 1984;58:212-214.
59. Ceda GP, Valenti G, Butturini U, Hoffman AR. Diminished pituitary responsiveness to growth hormone-releasing factor in aging male rats. Endocrinology. 1986;118:2109-2114.
60. Sonntag WE, Boyd RL. Chronic ethanol feeding inhibits plasma levels of insulin-like growth factor-1. Life Sci. 1988;43:1325-1330.
61. Sonntag WE, Hylka VW, Meites J. Impaired ability of old male rats to secrete growth hormone in vivo but not in vitro in response to hpGRF(1-44). Endocrinology. 1983;113:2305-2307.
62. Spik K, Sonntag WE. Increased pituitary response to somatostatin in aging male rats: relationship to somatostatin receptor number and affinity. Neuroendocrinology. 1989;50:489-494.
63. Sonntag WE, Forman LJ, Miki N, et al. Effects of CNS active drugs and somatostatin antiserum on growth hormone release in young and old male rats. Neuroendocrinology. 1981;33:73-78.
64. Sonntag WE, Gough MA. Growth hormone releasing hormone induced release of growth hormone in aging male rats: dependence on pharmacological manipulation and endogenous somatostatin release. Neuroendocrinology. 1988;47:482-488.
65. Sonntag WE, Gottschall PE, Meites J. Increased secretion of somatostatin-28 from hypothalamic neurons of aged rats in vitro. Brain Res. 1986;380:229-234.
66. Penalva A, Burguera B, Casabiell X, Tresguerres JA, Dieguez C, Casanueva FF. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin? Neuroendocrinology. 1989;49:551-554.
67. Ghigo E, Goffi S, Nicolosi M, et al. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. J Clin Endocrinol Metab. 1990;71: 1481-1485.
68. DeGennaro CV, Zoli M, Cocchi D, et al. Reduced growth hormone releasing factor (GHRF)-like immunoreactivity and GHRF gene expression in the hypothalamus of aged rats. Peptides. 1989;10:705-708.
69. De Gennaro CV, Colonna V, Fidone F, Cocchi D, Muller EE. Feedback effects of growth hormone on growth hormone-releasing hormone and somatostatin are not evident in aged rats. Neurobiol Aging. 1993;14: 503-507.
70. Lieberman SA, Mitchell AM, Marcus R, Hintz RL, Hoffman AR. The insulin-like growth factor I generation test: resistance to growth hormone with aging and estrogen replacement therapy. Horm Metab Res. 1994; 26:229-233.
71. Takahashi S, Meites J. GH binding to liver in young and old female rats: relation to somatomedin-C secretion. Proc Soc Exp Biol Med. 1987;186: 229-233.
72. Xu X, Bennett SA, Ingram RL, Sonntag WE. Decreases in growth hormone receptor signal transduction contribute to the decline in insulin-like growth factor I gene expression with age. Endocrinology. 1995;136: 4551-4557.
73. Campbell GS, Pang L, Miyasaka T, Saltiel AR, Carter-Su C. Stimulation by growth hormone of MAP kinase activity in 3T3-F442A fibroblasts. J Biol Chem. 1992;267:6074-6080.
74. Argetsinger LS, Campbell GS, Yang X, et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell. 1993;74: 237-244.
75. Sotiropoulos A, Perrot-Applanat M, Dinerstein H, et al. Distinct cytoplasmic regions of the growth hormone receptor are required for activation of JAK2, mitogen-activated protein kinase, and transcription [see comments]. Endocrinology. 1994;135:1292-1298.
76. Gronowski AM, Zhong Z, Wen Z, Thomas MJ, Darnell JEJ, Rotwein P. In vivo growth hormone treatment rapidly stimulates the tyrosine phosphorylation and activation of Sta3. Mol Endocrinol. 1995;9:171-177.
77. Roupas P, Herington AC. Postreceptor signaling mechanisms for growth hormone. Trends Endocrinol Metab. 1994;5:154-158.
78. Bichell DP, Kikuchi K, Rotwein P. Growth hormone rapidly activates insulin-like growth factor I gene transcription in vivo. Mol Endocrinol. 1992;6:1899-1908.
79. D'Costa AP, Xu X, Ingram RL, Sonntag WE. Insulin-like growth factor-1 stimulation of protein synthesis is attenuated in cerebral cortex of aging rats. Neuroscience. 1995;65:805-813.
80. Carvalho CR, Brenelli SL, Silva AC, Nunes AL, Velloso LA, Saad MJ. Effect of aging on insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of rats. Endocrinology. 1996;137:151-159.
81. Xu X, Sonntag WE. Growth hormone-induced nuclear translocation of Stat-3 decreases with age: modulation by caloric restriction. Am J Physiol. 1996;271:E903-E909.
82. Breese CR, Ingram RL, Sonntag WE. Influence of age and long-term dietary restriction on plasma insulin-like growth factor (IGF-1), IGF-1 gene expression, and IGF-1 binding proteins. J Gerontol Biol Sci. 1991; 46:B180-B187.
83. D'Costa AP, Lenham JE, Ingram RL, Sonntag WE. Moderate caloric restriction increases type 1 IGF receptors and protein synthesis in aging rats. Mech Ageing Dev. 1993;71:59-71.
84. Murphy LJ, Bell GI, Friesen HG. Tissue distribution of insulin-like growth factor I and II messenger ribonucleic acid in the adult rat. Endocrinology. 1987;120:1279-1282.
85. D'Ercole AJ, Stiles AD, Underwood LE. Tissue concentrations of somatomedin-C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Nail Acad Sci USA. 1984;81:935(Abstract).
86. Noguchi T, Kurata LM, Sugisaki T. Presence of a somatomedin-C-immunoreactive substance in the central nervous system: immunohistochemical mapping studies. Neuroendocrinology. 1987;46:277-282.
87. Delafontaine P, Lou H, Alexander RW. Regulation of insulin-like growth factor I messenger RNA levels in vascular smooth muscle cells. Hypertension. 1991;18:742-747.
88. Werther GA, Abate M, Hogg A, et al. Localization of insulin-like growth factor-I mRNA in rat brain by in situ hybridization - relationship to IGF-I receptors. Mol Endocrinol. 1990;4:773-778.
89. Delafontaine P, Bernstein KE, Alexander RW. Insulin-like growth factor I gene expression in vascular cells. Hypertension. 1991;17:693-699.
90. Florini JR, Prinz PN, Vitiello MV, Hintz RL. Somatomedin-C levels in healthy young and old men: relationship to peak and 24-hour integrated levels of growth hormone. J Gerontol. 1985;40:2-7.
91. Sonntag WE, Boyd RL, Booze RM. Somatostatin gene expression in hypothalamus and cortex of aging male rats. Neurobiol Aging. 1990; 11:409-416.
92. Sonntag WE, Xu X, Ingram RL, D'Costa A. Moderate caloric restriction alters the subcellular distribution of somatostatin mRNA and increases growth hormone pulse amplitude in aged animals. Neuroendocrinology. 1995;61:601-608.
93. Berelowitz M, Firestone SL, Frohman LA. Effects of growth hormone excess and deficiency on hypothalamic somatostatin content and release and on tissue somatostatin distribution. Endocrinology. 1981;109: 714-719.
94. Chomczynski P, Downs TR, Frohman LA. Feedback regulation of growth hormone (GH)-releasing hormone gene expression by GH in rat hypothalamus. Mol Endocrinol. 1988;2:236-241.
95. Katakami H, Downs TR, Frohman LA. Effect of hypophysectomy on hypothalamic growth hormone-releasing factor content and release in the rat. Endocrinology. 1987;120:1079-1082.
96. Aziz N, Munro HN. Both subunits of rat liver ferritin are regulated at a translational level by iron induction. Nucleic Acids Res. 1986;14:915-927.
97. Aziz N, Munro HN. Iron regulates ferritin mRNA translation through a segment of its 5′ untranslated region. Proc Natl Acad Sci USA. 1987;84:8478-8482.
98. Welsh M, Scherberg N, Gilmore R, Steiner DF. Translational control of insulin biosynthesis. Evidence for regulation of elongation, initiation and signal-recognition-particle-mediated translational arrest by glucose. Biochem J. 1986;235:459-467.
99. Meyuhas O, Thompson EAJ, Perry RP. Glucocorticoids selectively inhibit translation of ribosomal protein mRNAs in P1798 lymphosarcoma cells. Mol Cell Biol. 1987;7:2691-2699.
100. Hentze MW, Caughman SW, Rouault TA, et al. Identification of the iron-responsive element for the translational regulation of human ferritin mRNA. Science. 1987;238:1570-1573.
101. Hentze MW, Rouault TA, Caughman SW, et al. A cis-acting element is necessary and sufficient for translational regulation of human ferritin expression in response to iron. Proc Natl Acad Sci USA. 1987;84: 6730-6734.
102. Walden WE, Patino MM, Gaffield L. Purification of a specific repressor of ferritin mRNA translation from rabbit liver. J Biol Chem. 1989;264: 13765-13769.
103. Rouault TA, Hentze MW, Haile DJ, Harford JB, Klausner RD. The iron-responsive element binding protein: a method for the affinity purification of a regulatory RNA-binding protein. Proc Natl Acad Sci USA. 1989;86: 5768-5772.
104. Eisenstein RS, Munro HN. Translational regulation of ferritin synthesis by iron [Review; 67 refs]. Enzyme. 1990;44:42-58.
105. Hershey JW. Translational control in mammalian cells [Review; 245 refs]. Annu Rev Biochem. 1991;60:717-755.
106. Xu X, Sonntag WE. Moderate caloric restriction prevents the age-related decline in growth hormone receptor signal transduction. J Gerontol Biol Sci. 1996;51A:B167-B174.
107. Fan J, Char D, Bagby GJ, Gelato MC, Lang CH. Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by tumor necrosis factor. Am J Physiol. 1995;269:R1204-R1212.
108. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest. 1994;94:1543-1549.
109. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA. 1994;91:4854-4858.
110. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271:665-668.
111. Kellerer M, Haring HU. Pathogenesis of insulin resistance: modulation of the insulin signal at receptor level [Review; 36 refs]. Diabetes Res Clin Practice. 1995;28(suppl):S173-S177.
112. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993;268:26055-26058.
113. Kelley KW, Brief S, Westly HJ, et al. GH3 pituitary adenoma cells can reverse thymic aging in rats. Proc Natl Acad Sci USA. 1986;83:5663-5667.
114. Khansari DN, Gustad T. Effects of long-term, low-dose growth hormone therapy on immune function and life expectancy of mice. Mech Ageing Dev. 1991;57:87-100.
115. Foster JA, Rich CB, Miller M, Benedict MR, Richman RA, Florini JR. Effect of age and IGF-I administration on elastin gene expression in rat aorta. J Gerontol Biol Sci. 1990;45:B113-B118.
116. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old [see comments]. N Engl J Med. 1990;323:1-6.
117. Marcus R, Butterfield G, Holloway L, et al. Effects of short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab. 1990;70:519-527.
118. Kaiser FE, Silver AJ, Morley JE. The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc. 1991;39:235-240.
119. Weltman A, Weltman JY, Schurrer R, Evans WS, Veldhuis JD, Rogol AD. Endurance training amplifies the pulsatile release of growth hormone: effects of training intensity. J Appl Physiol. 1992;72:2188-2196.
120. Amano T, Meyer JS, Okabe T, Shaw T, Mortel KF. Stable xenon CT cerebral blood flow measurements computed by a single compartment-double integration model in normal aging and dementia. J Computer Assist Tomography. 1982;6:923-932.
121. Bell MA, Ball MJ. Neuritic plaques and vessels of visual cortex in aging and Alzheimer's dementia. Neurobiol Aging. 1990;11:359-370.
122. Goldman H, Berman RF, Gershon S, Murphy SL, Altman HJ. Correlation of behavioral and cerebrovascular functions in the aging rat. Neurobiol Aging. 1987;8:409-416.
123. Jucker M, Battig K, Meier-Ruge W. Effects of aging and vincamine derivatives on pericapillary microenvironment: stereological characterization of the cerebral capillary network [published erratum appears in Neurobiol Aging. 1990;11:675].Neurobiol Aging. 1990;11:39-46.
124. Kety SS. Human cerebral blood flow and oxygen consumption as related to aging. J Chronic Dis. 1956;8:478-486.
125. Melarned E, Lavy S, Bentin S, Cooper G, Rinot Y. Reduction in regional cerebral blood flow during normal aging in man. Stroke. 1980;11:31-35.
126. Shaw TG, Mortel KF, Meyer JS, Rogers RL, Hardenberg J, Cutaia MM. Cerebral blood flow changes in benign aging and cerebrovascular disease. Neurology. 1984;34:855-862.
127. Cook JJ, Wailgum TD, Vasthare US, Mayrovitz HN, Tuma RF. Age-related alterations in the arterial microvasculature of skeletal muscle. J Gerontol Biol Sci. 1992;47:B83-B88.
128. Hutchins PM, Dusseau JW, Marr MC, Greenbough WT. The role of arteriolar structural changes in hypertension. In: Henrich H, ed. Microvascular Aspects of Spontaneous Hypertension. Bern, Switzerland: Hans Huber; 1982:41-53.
129. Hutchins PM, Lynch CD, Cooney PT, Curseen KA. The microcirculation in experimental hypertension and aging [Review; 53 refs]. Cardiovasc Res. 1996;32:772-780.
130. Rosenblum WI, Kontos HA. The importance and relevance of studies of the pial microcirculation. Stroke. 1974;5:425-428.
131. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system [Review; 162 refs]. Cardiovasc Res. 1995;30: 825-834.
132. Folkow B, Isaksson OP, Karlstrom G, Lever AF, Nordlander M. The importance of hypophyseal hormones for structural cardiovascular adaptation in hypertension. J Hypertens [Suppl]. 1988;6:S166-S169.
133. Gould J, Aramburo C, Capdevielle M, Scanes CG. Angiogenic activity of anterior pituitary tissue and growth hormone on the chick embryo chorioallantoic membrane: a novel action of GH. Life Sci. 1995;56:587-594.
134. Hansson HA, Brandsten C, Lossing C, Petruson K. Transient expression of insulin-like growth factor I immunoreactivity by vascular cells during angiogenesis. Exp Mol Pathol. 1989;50:125-138.
135. Hansson HA, Jennische E, Skottner A. Regenerating endothelial cells express insulin-like growth factor-I immunoreactivity after arterial injury. Cell Tissue Res. 1987;250:499-505.
136. Sato Y, Okamura K, Morimoto A, et al. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp Cell Res. 1993; 204:223-229.
137. Grant MB, Mames RN, Fitzgerald C, et al. Insulin-like growth factor I as an angiogenic agent. In vivo and in vitro studies. Ann NY Acad Sci. 1993;692:230-242.
138. Nakao-Hayashi J, Ito H, Kanayasu T, Monta I, Murota S. Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis. 1992;92:141-149.
139. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol. 1994;145:1023-1029.
140. Engelmann GL, Boehm KD, Haskell JF, Khairallah PA, Ilan J. Insulin-like growth factors and neonatal cardiomyocyte development: ventricular gene expression and membrane receptor variations in normotensive and hypertensive rats. Mol Cell Endocrinol. 1989;63:1-14.
141. Creedon D, Tuttle JB. Nerve growth factor synthesis in vascular smooth muscle. Hypertension. 1991;18:730-741.
142. Shemer J, Raizada MK, Masters BA, Ota A, LeRoith D. Insulin-like growth factor I receptors in neuronal and glial cells. Characterization and biological effects in primary culture. J Biol Chem. 1987;262:7693-7699.
143. Femyhough P, Mill JF, Roberts JL, Ishii DN. Stabilization of tubulin mRNAs by insulin and insulin-like growth factor I during neurite formation. Brain Res Molec Brain Res. 1989;6:109-120.
144. Lenoir D, Honegger P. Insulin-like growth factor I (IGF I) stimulates DNA synthesis in fetal rat brain cell cultures. Brain Res. 1983;283: 205-213.
145. Han VK, Lauder JM, D'Ercole AJ. Rat astroglial somatomedin/insulin-iike growth factor binding proteins: characterization and evidence of biologic function. J Neurosci. 1988;8:3135-3143.
146. Torres-Aleman I, Naftolin F, Robbins RJ. Growth promoting effects of IGF-I on fetal hypothalamic cell lines under serum-free culture conditions. Int J Dev Neurosci. 1989;7:195-202.
147. Recio-Pinto E, Ishii DN. Effects of insulin, insulin-like growth factor-II and nerve growth factor on neurite outgrowth in cultured human neuroblastoma cells. Brain Res. 1984;302:323-334.
148. Recio-Pinto E, Lang FF, Ishii DN. Insulin and insulin-like growth factor II permit nerve growth factor binding and the neunte formation response in cultured human neuroblastoma cells. Proc Natl Acad Sci USA. 1984; 81:2562-2566.
149. Toran-Allerand CD, Ellis L, Pfenninger KH. Estrogen and insulin synergism in neurite growth enhancement in vitro: mediation of steroid effects by interactions with growth factors? Brain Res. 1988;469:87-100.
150. McMorris FA, Smith TM, DeSalvo S, Furlanetto RW. Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl Acad Sci USA. 1986;83:822-826.
151. McMorris FA, Dubois-Dalcq M. Insulin-like growth factor I promotes cell proliferation and oligodendroglial commitment in rat glial progenitor cells developing in vitro. J Neurosci Res. 1988;21:199-209.
152. Saneto RP, Low KG, Melner MH, de Vellis J. Insulin/insulin-like growth factor I and other epigenetic modulators of myelin basic protein expression in isolated oligodendrocyte progenitor cells. J Neurosci Res. 1988; 21:210-219.
153. van der Pal RH, Koper JW, van Golde LM, Lopes-Cardozo M. Effects of insulin and insulin-like growth factor (IGF-I) on oligodendrocyte-enriched glial cultures. J Neurosci Res. 1988;19:483-490.
154. Recio-Pinto E, Rechler MM, Ishii DN. Effects of insulin, insulin-like growth factor-II, and nerve growth factor on neunte formation and survival in cultured sympathetic and sensory neurons. J Neurosci. 1986;6: 1211-1219.
155. Ishii DN. Relationship of insulin-like growth factor II gene expression in muscle to synaptogenesis. Proc Natl Acad Sci USA. 1989;86:2898-2902.
156. Kanje M, Skottner A, Sjoberg J, Lundborg G. Insulin-like growth factor I (IGF-I) stimulates regeneration of the rat sciatic nerve. Brain Res. 1989; 486:396-398.
157. Ghahary A, Shen Q, Shen YJ, Scott PG, Tredget EE. Induction of transforming growth factor beta 1 by insulin-like growth factor-1 in dermal fibroblasts. J Cell Physiol. 1998;174:301-309.
158. Renganathan M, Sonntag WE, Delbono O. L-type Ca2+ channel-insulin-like growth factor-1 receptor signaling impairment in aging rat skeletal muscle. Biochem Biophys Res Commun. 1997;235:784-789.
159. Hepler JE, Lund PK. Molecular biology of the insulin-like growth factors. Relevance to nervous system function [Review; 205 refs]. Mol Neurobiol. 1990;4:93-127.
160. Hynes MA, Van Wyk JJ, Brooks PJ, D'Ercole AJ, Jansen M, Lund PK. Growth hormone dependence of somatomedin-C/insulin-like growth factor-I and insulin-like growth factor-II messenger ribonucleic acids. Mol Endocrinol. 1987;1:233-242.
161. Lopez-Fernandez J, Sanchez-Franco F, Velasco B, Tolon RM, Pazos F, Cacicedo L. Growth hormone induces somatostatin and insulin-like growth factor I gene expression in the cerebral hemispheres of aging rats. Endocrinology. 1996;137:4384-4391.
162. Pulford BE, Whalen LR, Ishii DN. Subcutaneous IGF administration spares loss of the limb withdrawal reflex in 6-OHDA lesioned rats. Soc Neurosci Abstracts. 1997;23:1705.
163. Reinhardt RR, Bondy CA. Insulin-like growth factors cross the blood-brain barrier. Endocrinology. 1994;135:1753-1761.
164. Markowska AL, Mooney M, Sonntag WE. Insulin-like growth factor-1 (IGF-1) ameliorates age-related behavioral deficits. Neuroscience. 1998; 87:559-569.
165. Bennett SA, Xu X, Lynch CD, Sonntag WE. Insulin-like growth factor-1 (IGF-1) regulates NMDAR1 in the hippocampus of aged animals. Soc Neurosci Abstracts. 1997;23:349.
166. Thornton PL, Bennett SA, Childers SR, Sonntag WE. Insulin-like growth factor reverses age related D2 receptor deficits: activity, intrinsic efficacy, and receptor reserve. (Submitted for publication.)
167. Altman HJ, Quartermain D. Facilitation of memory retrieval by centrally administered catecholamine stimulating agents. Behav Brain Res. 1983; 7:51-63.
168. Dubrovina NI, Il'iuchenok RI. The role of the dopaminergic system and GABA-benzodiazepine-ionophore complex in the regulation of memory retrieval. (in Russian). FIZIOL. 1990;36:3-8.
169. Shaywitz BA, Pearson DA. Effect of phenobarbital on activity and learning in 6-hydroxydopamine treated rat pups. Pharmacol Biochem Behav. 1978;9:173-179.
170. Smith RD, Cooper BR. Breese GR. Growth and behavioral changes in developing rats treated intracisternally with 6-hydroxydopamine: evidence for involvement of brain dopamine. J Pharmacol Exp Ther. 1973; 185:609-619.
171. Gasbarri A, Introini-Collison IB, Packard MG, Pacitti C, McGaugh JL. Interaction of cholinergic-dopaminergic systems in the regulation of memory storage in aversively motivated learning tasks. Brain Res. 1993;627:72-78.
172. Forster MJ, Dubey A, Dawson KM, Stutts WA, Lal H, Sohal RS. Age-related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain. Proc Natl Acad Sci USA. 1996;93:4765-4769.
173. Dubey A, Forster MJ, Lal H, Sohal RS. Effect of age and caloric intake on protein oxidation in different brain regions and on behavioral functions of the mouse. Arch Biochem Biophys. 1996;333:189-197.
174. Nelson JF. The potential role of selected endocrine systems in aging processes. In: Masoro EJ, ed. Handbook of Physiology, Section 11: Aging. New York: Oxford University Press; 1995:377-394.
175. Russell WE, Van Wyk JJ, Pledger WJ. Inhibition of the mitogenic effects of plasma by a monoclonal antibody to somatomedin C. Proc Natl Acad Sci USA. 1984;81:2389-2392.
176. Pietrzkowski Z, Sell C, Lammers R, Ullrich A, Baserga R. Roles of insulinlike growth factor 1 (IGF-1) and the IGF-1 receptor in epidermal growth factor-stimulated growth of 3T3 cells. Mol Cell Biol. 1992;12: 3883-3889.
177. Pietrzkowski Z, Wernicke D, Porcu P, Jameson BA, Baserga R. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res. 1992;52:6447-6451.
178. Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer [Review; 184 refs]. Adv Cancer Res. 1996;68:183-223.
179. Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol. 1990;10:464-473.
180. Lahm H, Amstad P, Wyniger J, et al. Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop. Int J Cancer. 1994;58:452-459.
181. Gansler T, Furlanetto R, Gramling TS, et al. Antibody to type I insulin-like growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice. Am J Pathol 1989;135:961-966.
182. Raile K, Hoflich A, Kessler U, et al. Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor. J Cell Physiol. 1994;159:531-541.
183. Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res. 1994;54:2803-2807.
184. Furlanetto RW, Harwell SE, Baggs RB. Effects of insulin-like growth factor receptor inhibition on human melanomas in culture and in athymic mice. Cancer Res. 1993;53:2522-2526.
185. El-Badry OM, Romanus JA, Helman U, Cooper MJ, Rechler MM, Israel MA. Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J Clin Invest. 1989;84:829-839.
186. Peyrat JP, Bonneterre J. Type 1 IGF receptor in human breast diseases [Review; 32 refs]. Breast Cancer Res Treat. 1992;22:59-67.
187. McCubrey JA, Steelman LS, Mayo MW, Algate PA, Dellow RA, Kaleko M. Growth-promoting effects of insulin-like growth factor-1 (IGF-1) on hematopoietic cells: overexpression of introduced IGF-1 receptor abrogates interleukin-3 dependency of murine factor-dependent cells by a ligand-dependent mechanism. Blood. 1991;78:921-929.
188. Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 1989;49:6237-6241.
189. Steger RW, Bartke A, Cecim M. Premature ageing in transgenic mice expressing different growth hormone genes. J Reprod Fertil [Suppl]. 1993;46:61-75.
190. Osborne CK, Clemmons DR, Arteaga CL. Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem Mol Biol. 1990; 37:805-809.
191. Brunner N, Moser C, Clarke R, Cullen K. IGF-I and IGF-II expression in human breast cancer xenografts: relationship to hormone independence [Review; 22 refs]. Breast Cancer Res Treat. 1992;22:39-45.
192. Lee AV, Darbre P, King RJ. Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Mol Cell Endocrinol. 1994;99: 211-220.
193. Torrisi R, Pensa F, Orengo MA, et al. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res. 1993;53:4769-4771.
194. Ankrapp DP, Bevan DR. Insulin-like growth factor-I and human lung fibroblast-derived insulin-like growth factor-I stimulate the proliferation of human lung carcinoma cells in vitro. Cancer Res. 1993;53:3399-3404.
195. Shigematsu K, Kataoka Y, Kamio T, Kurihara M, Niwa M, Tsuchiyama H. Partial characterization of insulin-like growth factor I in primary human lung cancers using immunohistochemical and receptor autoradiographic techniques. Cancer Res. 1990;50:2481-2484.
196. Rotsch M, Maasberg M, Erbil C, Jaques G, Worsch U, Havemann K. Characterization of insulin-like growth factor I receptors and growth effects in human lung cancer cell lines. J Cancer Res Clin Oncol. 1992; 118:502-508.
197. Kaiser U, Schardt C, Brandscheidt D, Wollmer E, Havemann K. Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer. J Cancer Res Clin Oncol. 1993;119: 665-668.
198. Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate. 1998;35:165-177.
199. Khansari DN, Gustad T. Effects of long-term, low-dose growth hormone therapy on immune function and life expectancy of mice. Mech Ageing Dev. 1991;57:87-100.
200. Kalu DN, Orhii PB, Chen C, et al. Aged rodent models of long term growth hormone therapy: lack of deleterious effect on longevity. J Gerontol Biol Sci. 1998;53A:B452-B463.
201. Bartke A, Shire JG, Chandrashekar V, et al. Effects of human growth hormone on reproductive and neuroendocrine functions in transgenic mice [Review; 34 refs]. Biotechnology. 1991;16:237-248.
202. Bartke A, Steger RW, Hodges SL, Parkening TA, Collins TJ, Yun JS, Wagner TE. Infertility in transgenic female mice with human growth hormone expression: evidence for luteal failure. J Exp Zool. 1988; 248:121-124.
203. Bartke A, Cecim M, Tang K, Steger RW, Chandrashekar V, Turyn D. Neuroendocrine and reproductive consequences of overexpression of growth hormone in transgenic mice [Review; 110 refs]. Proc Soc Exp Biol Med. 1994;206:345-359.
204. Steger RW, Bartke A, Parkening TA, et al. Effects of heterologous growth hormones on hypothalamic and pituitary function in transgenic mice. Neuroendocrinology. 1991;53:365-372.
205. 2]GHRH administration increases working memory in aged animals. Soc Neurosci Abstr. 1997;23:532.
206. Brown-Borg HM, Borg KE, Meliska CJ, Bartke A. Dwarf mice and the ageing process [letter]. Nature. 1996;384:33.
207. Andersen B, Pearse RV, Jenne K, et al. The Ames dwarf gene is required for Pit-1 gene activation. Dev Biol. 1995;172:495-503.
208. Xu X, Sonntag WE. Moderate caloric restriction prevents the age-related decline in growth hormone receptor signal transduction. J Gerontol Biol Sci. 1996;51A:B167-B174.
209. Lynch CD, Cooney PT, Bennett SA, et al. Effects of moderate caloric restriction on cortical microvascular density and local cerebral blood flow in aged rats. Neurobiol Aging. (in press).
210. Sonntag WE, Lynch CD, Cooney PT, Hutchins PM. Decreases in cerebral microvasculature with age are associated with the decline in growth hormone and insulin-like growth factor 1. Endocrinology. 1997;138: 3515-3520.
211. Sonntag WE, Lynch CD, Bennett SA, et al. Alterations in insulin-like growth factor-1 gene and protein expression and type 1 insulin-like growth factor receptors in the brains of ageing rats. Neuroscience. 1999;88:269-279.
212. Pendergrass WR, Li Y, Jiang D, Wolf NS. Decrease in cellular replicative potential in "giant" mice transfected with the bovine growth hormone gene correlates to shortened life span. J Cell Phvsiol. 1993;156:96-103.
213. Pendergrass WR, Li Y, Jiang D, Fei RG, Wolf NS. Caloric restriction: conservation of cellular replicative capacity in vitro accompanies lifespan extension in mice. Exp Cell Res. 1995;217:309-316.
214. Sonntag WE, Ingram RL, Bennett S, et al. Moderate caloric restriction increases growth hormone pulse amplitude and improves insulin sensitivity in aged rodents. Presented at the 10th International Congress of Endocrinology; July, 1996; San Francisco, CA.